Figure 1.

Droplet digital polymerase chain reaction (ddPCR) analysis at the time of imatinib cessation stratifies STIM2 participants according to probability of successful treatment-free remission (TFR). Among 175 patients for whom BCR-ABL1 ddPCR data was collected and expressed on the international scale, 100 patients were ddPCR-negative and 75 patients were ddPCR-positive. For TFR probability analysis, the 37 ddPCR-positive patients below the median value were grouped with the ddPCR-negative patients. The other group was comprised of the 37 ddPCR-positive patients above the median value. The TFR values shown are for the two groups at twelve months post-imatinib cessation.